Completed PHASE2 INTERVENTIONAL 2-arm NCT01478737

Intravitreal Ozurdex After Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

A Prospective, Randomized Study on Intravitreal Ozurdex for Preventing Recurrent Vitreous Hemorrhage Following Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy

Sponsor: Anders Kvanta

Conditions Proliferative Diabetic Retinopathy

Interventions Intravitreal dexamethasone implant Vitrectomy

Updated 6 times since 2017 Last updated: Jan 28, 2024 Started: Nov 30, 2011 Primary completion: Apr 30, 2016 Completion: Apr 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Proliferative Diabetic Retinopathy, this trial is completed. The trial is conducted by Anders Kvanta and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Unknown Status → Completed
Jan 2021 — Feb 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Anders Kvanta

Data source: St. Erik Eye Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stockholm, Sweden